FOLH1 and Familial prostate cancer: Furthermore, the prevalence calculated for PSL among cancer patients and prostate cancer patients alone are likely understated because they are based on the total number of FDG and PSMA PET/CT studies for suspected and confirmed malignancies, and we could not distinguish between those with definite cancers and in particular, those with disseminated disease.